Program accrues most patients into radiation research program and completes 100% timeliness data submission scores
The Woodlands, Texas — US Oncology Research, supported by McKesson Specialty Health, has been recognized by Radiation Therapy Oncology Group® (RTOG®), the leader in radiation oncology-focused clinical trials in the United States, as the top site of all full member and provisional institutions for accruing patients into radiation research trials and timely submission of research data. With 19 RTOG approved community-based sites, US Oncology Research sites accrued 64 patients to RTOG trials in 2011 and achieved 100% timeliness data submission scores.
"Receiving top honors from RTOG is a credit to all the members of the radiation research team including the doctors, clinical research coordinators and the central research staff who work so tirelessly in support of patients and the program," said Vivek Kavadi, M.D., medical director of Radiation Oncology for The US Oncology Network and radiation oncologist with Texas Oncology-Sugar Land, a practice participating in US Oncology Research.
US Oncology Research earned full RTOG member status in June 2011 and has been accruing patients into RTOG clinical trials since 2008. All together, since joining RTOG, US Oncology Research affiliated physicians have enrolled 227 patients into RTOG clinical trials, and more than 50,000 patients to oncology clinical trials overall. Annually, the RTOG Membership Evaluation Committee evaluates its members for number of patients accrued and timeliness of data submission. US Oncology Research was the top site in both categories.
US Oncology Research is one of the strongest and most reputable community research networks in the world. Collectively, its affiliated physicians and research professionals have contributed greatly to advancing the science of cancer care and improved patient outcomes.
Practices affiliated with US Oncology Research are located across the country allowing cancer patients to receive cutting-edge radiation and integrated therapy clinical trials in their hometowns close to their support system of friends and families.
About US Oncology Research
McKesson Specialty Health conducts clinical trials through US Oncology Research, which draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in over 250 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 50,000 patients in over 1,200 trials since inception and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.
About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we can improve the financial health of our customers and help them provide quality care for patients. For more information, visit www.mckessonspecialtyhealth.com.
About Radiation Therapy Oncology Group
Radiation Therapy Oncology Group is a dynamic multidisciplinary group with vigorous participation by physicians and other researchers from more than 350 of the leading academic and community medical facilities in the United States, Canada and internationally, including nearly 90 percent of all NCI-designated cancer centers and many of the major academic and regional centers of Canada. This participation includes leadership from medical oncologists, surgical oncologists, pathologists, and laboratory scientists as well radiation oncologists. All Group research efforts seek to be transformational in nature, with the goal of improving the quantity and quality of survival of cancer patients. For more information, visit www.RTOG.org.
PR Contact
Contact Public Relations